US EditionBracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency
- Bracco Imaging's SonoVue® has received regulatory approval from China's National Medical Products Administration for use in hysterosalpingo contrast sonography procedures.
- HyCoSy is a non-invasive ultrasound procedure that accurately identifies causes of female infertility related to fallopian tube blockages or uterine abnormalities.
- The NMPA approval is significant for infertility management, providing a non-invasive alternative to laparoscopic assessment.
- This approval enhances access to non-invasive detection of infertility causes, aligning with national health objectives in China.
- Bracco Imaging aims to enhance diagnostic precision and improve patient care standards in China and globally.
Insights by Ground AI
Does this summary seem wrong?
57 Articles
57 Articles
China NMPA approves Bracco Imaging's contrast agent for infertility diagnosis
China's NMPA has approved Bracco Imaging's ultrasound contrast agent, sulphur hexafluoride (SF6) microbubbles.The post China NMPA approves Bracco Imaging’s contrast agent for infertility diagnosis appeared first on Medical Device Network.
Bracco Imaging Receives Regulatory Approval in China for SonoVue in the Assessment of Fallopian Tube Patency
New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 6, 2025 /PRNewswire/ — Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China’s National Medical Products Administration (NMPA) for use in hysterosalpingo contrast sonography (HyCoSy). […] The post Bracco Imaging Recei…
Coverage Details
Total News Sources57
Leaning Left4Leaning Right7Center13Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 17%
C 54%
R 29%
Factuality
To view factuality data please Upgrade to Premium
